{"id":"sermorelin","rwe":[],"tags":[{"label":"sermorelin","category":"class"},{"label":"Peptide","category":"modality"},{"label":"Growth hormone-releasing hormone receptor","category":"target"},{"label":"GHRHR","category":"gene"},{"label":"H01AC04","category":"atc"},{"label":"Off-Patent","category":"patent"},{"label":"Active","category":"status"},{"label":"Diagnostic Test for Growth Hormone Secretion","category":"indication"},{"label":"Pituitary dwarfism","category":"indication"},{"label":"Approved 1990s","category":"decade"}],"phase":"marketed","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=sermorelin","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T03:22:24.476194+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T03:22:30.048696+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=sermorelin","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T03:22:30.250405+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Growth hormone-releasing hormone receptor agonist","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:22:31.364555+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1201490/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:22:31.026836+00:00"}},"allNames":"geref","offLabel":[],"synonyms":["sermorelin acetate","sermorelin","somatoliberin"],"timeline":[{"date":"1990-12-28","type":"positive","source":"DrugCentral","milestone":"FDA approval"},{"date":"1997-09-26","type":"positive","source":"FDA Orange Book","milestone":"Geref approved — EQ 0.5MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**"}],"aiSummary":"Geref (sermorelin) is a small molecule drug that targets the growth hormone-releasing hormone receptor. Originally developed by a pharmaceutical company, it is currently owned by Emd Serono and was FDA approved in 1990 for diagnostic testing of growth hormone secretion and treatment of pituitary dwarfism. As an off-patent medication with no active Orange Book patents, Geref is not commercially available as a generic. Key safety considerations include its short half-life of 0.19 hours. Geref is used to stimulate growth hormone release in the body.","approvals":[{"date":"1990-12-28","orphan":false,"company":"","regulator":"FDA"}],"brandName":"Geref","ecosystem":[{"indication":"Diagnostic Test for Growth Hormone Secretion","otherDrugs":[{"name":"arginine","slug":"arginine","company":"Pharmacia And Upjohn"}],"globalPrevalence":null},{"indication":"Pituitary dwarfism","otherDrugs":[{"name":"somatrem","slug":"somatrem","company":"Genentech"},{"name":"somatropin","slug":"somatropin","company":"Serono"}],"globalPrevalence":null}],"mechanism":{"target":"Growth hormone-releasing hormone receptor","novelty":"Follow-on","targets":[{"gene":"GHRHR","source":"DrugCentral","target":"Growth hormone-releasing hormone receptor","protein":"Growth hormone-releasing hormone receptor"}],"modality":"Peptide","drugClass":"sermorelin","explanation":"","oneSentence":"","technicalDetail":"Geref (sermorelin) is a synthetic decapeptide that mimics the action of growth hormone-releasing hormone (GHRH), binding to the GHRH receptor on the surface of pituitary somatotrophs and stimulating the release of growth hormone through a G-protein coupled receptor mechanism."},"commercial":{"launchDate":"1990","_launchSource":"DrugCentral (FDA 1990-12-28, )"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/2433","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=sermorelin","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=sermorelin","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T15:39:16.056239","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:22:32.576106+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"somatropin","drugSlug":"somatropin","fdaApproval":"1976-07-30","relationship":"same-class"},{"drugName":"somatrem","drugSlug":"somatrem","fdaApproval":"1985-10-17","relationship":"same-class"},{"drugName":"mecasermin","drugSlug":"mecasermin","fdaApproval":"2005-08-30","relationship":"same-class"},{"drugName":"mecasermin rinfabate","drugSlug":"mecasermin-rinfabate","fdaApproval":"2005-12-12","relationship":"same-class"},{"drugName":"tesamorelin","drugSlug":"tesamorelin","fdaApproval":"2010-11-10","relationship":"same-class"},{"drugName":"somapacitan","drugSlug":"somapacitan","fdaApproval":"2020-08-28","relationship":"same-class"},{"drugName":"somatrogon","drugSlug":"somatrogon","fdaApproval":"2023-06-27","relationship":"same-class"},{"drugName":"lonapegsomatropin","drugSlug":"lonapegsomatropin","fdaApproval":"2021-08-25","relationship":"same-class"}],"genericName":"sermorelin","indications":{"approved":[{"name":"Diagnostic Test for Growth Hormone Secretion","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Pituitary dwarfism","source":"DrugCentral","snomedId":367460001,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"currentOwner":"Emd Serono","drugCategory":"active","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"somatropin","brandName":"somatropin","genericName":"somatropin","approvalYear":"1976","relationship":"same-class"},{"drugId":"somatrem","brandName":"somatrem","genericName":"somatrem","approvalYear":"1985","relationship":"same-class"},{"drugId":"mecasermin","brandName":"mecasermin","genericName":"mecasermin","approvalYear":"2005","relationship":"same-class"},{"drugId":"mecasermin-rinfabate","brandName":"mecasermin rinfabate","genericName":"mecasermin rinfabate","approvalYear":"2005","relationship":"same-class"},{"drugId":"tesamorelin","brandName":"tesamorelin","genericName":"tesamorelin","approvalYear":"2010","relationship":"same-class"},{"drugId":"somapacitan","brandName":"somapacitan","genericName":"somapacitan","approvalYear":"2020","relationship":"same-class"},{"drugId":"somatrogon","brandName":"somatrogon","genericName":"somatrogon","approvalYear":"2023","relationship":"same-class"},{"drugId":"lonapegsomatropin","brandName":"lonapegsomatropin","genericName":"lonapegsomatropin","approvalYear":"2021","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT03375788","phase":"PHASE2","title":"Growth Hormone Releasing Hormone Analog to Improve Nonalcoholic Fatty Liver Disease and Associated Cardiovascular Risk","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2019-01-17","conditions":["Non-Alcoholic Fatty Liver Disease","Obesity","Obesity, Abdominal","Liver Fat","Fatty Liver"],"enrollment":51,"completionDate":"2025-01-10"},{"nctId":"NCT06554717","phase":"PHASE2","title":"Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2025-07-07","conditions":["HIV-1-infection","Frailty","Impaired Physical Function","Abdominal Obesity","Aging"],"enrollment":100,"completionDate":"2028-06-30"},{"nctId":"NCT00720902","phase":"PHASE4","title":"Adult Growth Hormone Deficiency and Cardiovascular Risk","status":"TERMINATED","sponsor":"Columbia University","startDate":"2007-02","conditions":["Growth Hormone Deficiency"],"enrollment":7,"completionDate":"2011-05"},{"nctId":"NCT00608023","phase":"PHASE3","title":"TH9507 Extension Study in Patients With HIV-Associated Lipodystrophy","status":"COMPLETED","sponsor":"Theratechnologies","startDate":"2007-08","conditions":["Lipodystrophy","HIV Infections"],"enrollment":263,"completionDate":"2008-10"},{"nctId":"NCT02196831","phase":"NA","title":"Tesamorelin Effects on Liver Fat and Histology in HIV","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2015-07-01","conditions":["Human Immunodeficiency Virus (HIV)","Nonalcoholic Fatty Liver Disease (NAFLD)","Nonalcoholic Steatohepatitis (NASH)"],"enrollment":61,"completionDate":"2019-07-24"},{"nctId":"NCT02553603","phase":"PHASE1","title":"The Effect of Growth Hormone Releasing Hormone on Cognitive Function in Individuals With Mild Cognitive Impairment","status":"COMPLETED","sponsor":"The University of Texas Medical Branch, Galveston","startDate":"2017-07-18","conditions":["Mild Cognitive Impairment"],"enrollment":22,"completionDate":"2019-01-17"},{"nctId":"NCT00791843","phase":"PHASE2","title":"The Effect of GHRH Therapy on Myocardial Structure and Function in Congestive Heart Failure","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2004-03","conditions":["Congestive Heart Failure"],"enrollment":3,"completionDate":"2011-08"},{"nctId":"NCT01410799","phase":"PHASE2","title":"Three Month Treatment of Growth Hormone Releasing Hormone (GHRH) in the Elderly","status":"TERMINATED","sponsor":"University of Pennsylvania","startDate":"2011-05","conditions":["Hormone Deficiency","Aging"],"enrollment":13,"completionDate":"2011-08"},{"nctId":"NCT00675506","phase":"PHASE2","title":"Effectiveness of Growth Hormone Releasing Hormone in Reducing Abdominal Fat in People Who Are Obese","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2008-07","conditions":["Abdominal Obesity","Growth Hormone Deficiency"],"enrollment":60,"completionDate":"2012-01"},{"nctId":"NCT01263717","phase":"NA","title":"Effects of Growth Hormone Releasing Hormone in HIV","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2010-12","conditions":["HIV","HIV Lipodystrophy"],"enrollment":54,"completionDate":"2014-02"},{"nctId":"NCT03031535","phase":"PHASE1","title":"Study of Intranasal Octreotide (DP1038) in Healthy Adult Volunteers","status":"COMPLETED","sponsor":"Dauntless Pharmaceuticals","startDate":"2017-01","conditions":["Healthy Volunteer Study"],"enrollment":32,"completionDate":"2017-03"},{"nctId":"NCT00807365","phase":"PHASE2","title":"Six Month Treatment of Growth Hormone Releasing Hormone (GHRH) in the Elderly","status":"TERMINATED","sponsor":"Johns Hopkins University","startDate":"2007-12-17","conditions":["Elderly"],"enrollment":5,"completionDate":"2010-04-29"},{"nctId":"NCT03018886","phase":"NA","title":"Diagnosing Adult Growth Hormone Deficiency","status":"COMPLETED","sponsor":"Helsinki University Central Hospital","startDate":"2001-05","conditions":["Growth Hormone Deficiency"],"enrollment":160,"completionDate":"2008-12"},{"nctId":"NCT02271282","phase":"PHASE1","title":"Estradiol-Receptor Blockade in Older Men and Women","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2014-12","conditions":["Normal Healthy Volunteers"],"enrollment":40,"completionDate":"2016-05"},{"nctId":"NCT02736591","phase":"PHASE3","title":"Dehydroepiandrosterone Versus Growth Hormone in Women Undergoing ICSI With Expected Poor Ovarian Response","status":"UNKNOWN","sponsor":"Cairo University","startDate":"2016-06","conditions":["Subfertility"],"enrollment":210,"completionDate":""},{"nctId":"NCT00000380","phase":"NA","title":"Growth Hormone Releasing Hormone (GHRH) Treatment for Age-Related Sleep Disturbances","status":"COMPLETED","sponsor":"University of Washington","startDate":"1996-06","conditions":["Sleep Disorders"],"enrollment":0,"completionDate":"2007-07"},{"nctId":"NCT02507245","phase":"","title":"Observational Longitudinal Study in Children Affected by Idiopathic Growth Hormone Deficiency (GHD)","status":"COMPLETED","sponsor":"Stefania La Grutta, MD","startDate":"2014-01","conditions":["Growth Hormone Deficiency"],"enrollment":48,"completionDate":"2015-05"},{"nctId":"NCT01060488","phase":"PHASE3","title":"Comparative Validation of the Growth Hormone Releasing Hormone and Arginine Test for the Diagnosis of Adult Growth Hormone Deficiency","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2004-01","conditions":["Growth Hormone Deficiency"],"enrollment":69,"completionDate":""},{"nctId":"NCT01632592","phase":"NA","title":"Abdominal Obesity, Cardiovascular Inflammation, and Effects of Growth Hormone Releasing Hormone Analogue","status":"WITHDRAWN","sponsor":"Massachusetts General Hospital","startDate":"2014-01","conditions":["Abdominal Obesity"],"enrollment":0,"completionDate":"2014-01"},{"nctId":"NCT00795210","phase":"NA","title":"Effects of Short-term Growth Hormone in HIV-infected Patients","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2009-02","conditions":["HIV Lipodystrophy"],"enrollment":25,"completionDate":"2012-11"},{"nctId":"NCT00257712","phase":"PHASE2","title":"SMART: Somatotrophics, Memory, and Aging Research Trial","status":"COMPLETED","sponsor":"University of Washington","startDate":"2006-02","conditions":["Aging","Mild Cognitive Impairment"],"enrollment":151,"completionDate":"2011-12"},{"nctId":"NCT02012556","phase":"PHASE1","title":"Pharmacokinetic and Pharmacodynamic Study of TH9507, a Growth Hormone-Releasing Factor Analog, in HIV Positive Patients","status":"COMPLETED","sponsor":"Theratechnologies","startDate":"2008-05","conditions":["HIV"],"enrollment":18,"completionDate":"2008-07"},{"nctId":"NCT00123253","phase":"PHASE3","title":"TH9507 in Patients With HIV-Associated Lipodystrophy","status":"COMPLETED","sponsor":"Theratechnologies","startDate":"2005-06","conditions":["HIV Infections","Lipodystrophy"],"enrollment":412,"completionDate":"2007-04"},{"nctId":"NCT01359488","phase":"PHASE1","title":"VRS-317 in Adult Subjects With Growth Hormone Deficiency","status":"COMPLETED","sponsor":"Versartis Inc.","startDate":"2011-03","conditions":["Growth Hormone Deficiency"],"enrollment":50,"completionDate":"2012-07"},{"nctId":"NCT00850564","phase":"NA","title":"Effect of Short Term Growth Hormone Releasing Hormone in Healthy Men","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2009-02","conditions":["Healthy Volunteers"],"enrollment":15,"completionDate":"2010-04"},{"nctId":"NCT00324064","phase":"NA","title":"Sexually Dimorphic Effects of GHRH in Adult Growth Hormone Testing","status":"COMPLETED","sponsor":"Children's Mercy Hospital Kansas City","startDate":"2007-07","conditions":["Growth Hormone Deficiency"],"enrollment":90,"completionDate":"2009-07"},{"nctId":"NCT00004332","phase":"","title":"Study of the Effect of Growth Hormone-Releasing Hormone Antagonist on Growth Hormone Release in Acromegaly","status":"COMPLETED","sponsor":"National Center for Research Resources (NCRR)","startDate":"1993-05","conditions":["Acromegaly"],"enrollment":148,"completionDate":""}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"_patentsChecked":true,"crossReferences":{"NUI":"N0000179347","MMSL":"5456","NDDF":"004104","UNII":"89243S03TE","VUID":"4019553","CHEBI":"CHEBI:9118","VANDF":"4019553","INN_ID":"6036","RXNORM":"56188","UMLSCUI":"C0142046","chemblId":"CHEMBL1201490","ChEMBL_ID":"CHEMBL1201490","KEGG_DRUG":"D02117","DRUGBANK_ID":"DB00010","PUBCHEM_CID":"16132413","SNOMEDCT_US":"109203000","IUPHAR_LIGAND_ID":"6998","SECONDARY_CAS_RN":"114466-38-5","MESH_DESCRIPTOR_UI":"D017337"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"present","companyName":"Emd Serono","relationship":"Current Owner"}],"pharmacokinetics":{"source":"DrugCentral","halfLife":"0.19 hours","clearance":"39.3 mL/min/kg","volumeOfDistribution":"0.34 L/kg"},"publicationCount":22,"therapeuticAreas":["Hematology"],"atcClassification":{"source":"DrugCentral","atcCode":"H01AC04","allCodes":["H01AC04","V04CD03"]},"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturers":0,"_genericFilersChecked":true,"genericManufacturerList":[],"status":"active","companyName":"Emd Serono","companyId":"unknown","modality":"Peptide","firstApprovalDate":"1990","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1990-12-28T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:22:32.576106+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}